Core Viewpoint - Permian Resources Corporation (PR) reported a first-quarter 2025 adjusted net income per share of 42 cents, missing the Zacks Consensus Estimate of 44 cents, primarily due to increased operating expenses and lower oil prices, although the figure was consistent with the previous year [1] Financial Performance - Oil and gas sales reached $1.4 billion, reflecting a 10.7% increase year-over-year but falling short of the Zacks Consensus Estimate by 1.2% [1] - Adjusted cash flow from operations increased by 13.9% to $960.5 million, with capital expenditures totaling $501 million, resulting in adjusted free cash flow of $460 million [6] - Total operating expenses rose to $872 million from $774.1 million in the prior year, driven by a 6.5% increase in lease operating costs and a 15.6% rise in depreciation, depletion, and amortization [5] Production and Pricing - Average daily production increased by 16.8% year-over-year to 373,209 barrels of oil equivalent (Boe), surpassing the Zacks Consensus Estimate of 368,855 Boe [3] - Oil volume for the quarter was 174,967 barrels per day, up 15.3% year-over-year, exceeding the consensus mark of 171,776 Bbls/d [3] - The average sales price for oil was $70.48 per barrel, down 7.4% from the previous year, and slightly below the consensus estimate [4] Dividend and Shareholder Returns - The board declared a quarterly cash dividend of 15 cents per share, equivalent to 60 cents annually, to be paid on June 30, 2025 [2] Strategic Moves - The company completed the sale of its non-core Barilla Draw gathering systems for $180 million during the quarter [2] - A strategic acquisition was announced, expected to contribute approximately 12,000 Boe/d in the second half of the year, although this is not included in the revised standalone guidance [10] Guidance and Outlook - Updated full-year 2025 guidance anticipates average daily production between 360,000-380,000 Boe/d, with oil production ranging from 170,000 Bbls/d to 175,000 Bbls/d [7] - Controllable cash expenses are projected to be between $7.25 and $8.25 per Boe, with lease operating expenses estimated at approximately $5.55 per Boe [8] - The capital expenditure budget has been slightly reduced to a range of $1.9-$2 billion [9]

Core Insights - LPL Financial Holdings Inc. reported a revenue of $3.69 billion for the quarter ended March 2025, marking a 30.3% increase year-over-year, with an EPS of $5.15 compared to $4.21 in the same quarter last year, exceeding both revenue and EPS consensus estimates [1] Financial Performance - Revenue exceeded the Zacks Consensus Estimate of $3.61 billion by 2.21%, while EPS surpassed the consensus estimate of $4.54 by 13.44% [1] - Total Advisory and Brokerage Assets reached $1,794.9 billion, below the average estimate of $1,816.08 billion [4] - Brokerage Assets were reported at $817.5 billion, slightly below the estimated $821.02 billion [4] - Advisory Assets totaled $977.4 billion, also below the average estimate of $995.07 billion [4] Revenue Breakdown - Revenue from commissions was $1.05 billion, exceeding the estimate of $960.89 million, representing a year-over-year increase of 40.4% [4] - Service and fee revenue was reported at $145.20 million, above the estimate of $139.93 million, reflecting a 9.9% year-over-year increase [4] - Asset-based fees generated $695.24 million, slightly below the estimate of $711.71 million, with a year-over-year change of 15.7% [4] - Advisory revenue was $1.69 billion, slightly above the estimate of $1.68 billion, showing a year-over-year increase of 40.8% [4] - Transaction revenue was $67.86 million, exceeding the estimate of $62.16 million, with an 18.5% year-over-year increase [4] - Other asset-based revenue was $303.21 million, above the estimate of $293.49 million [4] - Client cash revenue was $392.03 million, below the estimate of $415.02 million [4] - Trailing commission revenue was $437.72 million, slightly above the estimate of $436.23 million, with a year-over-year increase of 21.2% [4] Stock Performance - LPL Financial's shares returned 4.9% over the past month, compared to the S&P 500 composite's 11.3% change, with a current Zacks Rank of 3 (Hold) indicating potential performance in line with the broader market [3]

Core Insights - Toast reported revenue of $1.34 billion for the quarter ended March 2025, reflecting a year-over-year increase of 24.4% [1] - The company's EPS was $0.20, a significant improvement from -$0.15 in the same quarter last year [1] - Revenue met the Zacks Consensus Estimate, but there was a slight negative surprise of -0.27% [1] - EPS exceeded expectations with a surprise of +5.26% compared to the consensus estimate of $0.19 [1] Key Performance Metrics - Gross Payment Volume (GPV) was reported at $42.2 billion, slightly below the estimated $42.38 billion [4] - Subscription Annualized Recurring Run-Rate reached $883 million, surpassing the average estimate of $867.78 million [4] - The number of locations served by Toast was 140,000, close to the estimated 140,163 [4] - Total Annualized Recurring Run-Rate (ARR) was $1.71 billion, matching the average estimate [4] - Payments Annualized Recurring Run-Rate stood at $830 million, slightly above the estimate of $824.03 million [4] - Revenue from financial technology solutions was $1.08 billion, aligning with the average estimate [4] - Revenue from subscription services was $209 million, exceeding the average estimate of $201.35 million [4] - Revenue from hardware and professional services was $46 million, falling short of the estimated $53.03 million [4] Stock Performance - Toast's shares have returned +3.4% over the past month, compared to the S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Core Insights - The Beauty Health Company (SKIN) reported a revenue of $69.6 million for the quarter ended March 2025, reflecting a year-over-year decline of 14.5% [1] - The earnings per share (EPS) was -$0.08, an improvement from -$0.10 in the same quarter last year, with a positive surprise of 38.46% compared to the consensus estimate of -$0.13 [1] - The reported revenue exceeded the Zacks Consensus Estimate of $63.12 million by 10.26% [1] Financial Performance Metrics - Total delivery systems sold reached 862, surpassing the average estimate of 573 based on two analysts [4] - The active install base was reported at 35,014, slightly below the average estimate of 35,090 [4] - Geographic revenue breakdown showed: - Americas: $46.30 million, exceeding the estimate of $43.49 million, but down 8% year-over-year [4] - EMEA: $15 million, above the estimate of $13.60 million, with a year-over-year decline of 21.5% [4] - Asia Pacific: $8.30 million, surpassing the estimate of $6.98 million, down 30.8% year-over-year [4] - Delivery Systems Net Sales were $20.20 million, exceeding the estimate of $14.30 million, but down 43.6% year-over-year [4] - Consumables Net Sales reached $49.40 million, slightly above the estimate of $48.24 million, reflecting an increase of 8.3% year-over-year [4] Stock Performance - Shares of Beauty Health have increased by 31.5% over the past month, outperforming the Zacks S&P 500 composite, which rose by 11.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Post Holdings reported revenue of $1.95 billion for the quarter ended March 2025, a decrease of 2.4% year-over-year, and EPS of $1.41, down from $1.51 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $1.98 billion, resulting in a surprise of -1.28%, while the EPS exceeded expectations by 19.49% compared to the consensus estimate of $1.18 [1] Financial Performance Metrics - Net Sales for Weetabix were $131.70 million, below the estimated $133.10 million, reflecting a year-over-year decline of 4.6% [4] - Net Sales for Post Consumer Brands were reported at $987.90 million, compared to the average estimate of $1.02 billion, marking a 7.3% decrease year-over-year [4] - Net Sales for Foodservice reached $607.90 million, surpassing the average estimate of $584.58 million, with a year-over-year increase of 9.6% [4] - Net Sales for Refrigerated Retail were $224.60 million, below the average estimate of $237.73 million, indicating a 6.6% decline year-over-year [4] Adjusted EBITDA Performance - Adjusted EBITDA for Post Consumer Brands was $203.80 million, slightly below the average estimate of $204.92 million [4] - Adjusted EBITDA for Weetabix was $30.30 million, exceeding the estimated $27.17 million [4] - Adjusted EBITDA for Foodservice was $96 million, significantly above the average estimate of $75.40 million [4] - Adjusted EBITDA for Corporate/Other was -$18.30 million, better than the average estimate of -$23.60 million [4] - Adjusted EBITDA for Refrigerated Retail was $34.70 million, below the average estimate of $39.89 million [4] Stock Performance - Over the past month, shares of Post Holdings have returned -4.2%, contrasting with the Zacks S&P 500 composite's increase of +11.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Illumina reported revenue of $1.04 billion for the quarter ended March 2025, reflecting a 3.3% decrease year-over-year, while EPS increased to $0.97 from $0.09 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate by 0.25%, and the EPS also surpassed the consensus estimate by 1.04% [1] Revenue Breakdown - Product revenue was $880 million, slightly above the average estimate of $872.04 million, marking a year-over-year increase of 0.5% [4] - Core Illumina service and other revenue totaled $161 million, below the average estimate of $175.08 million, representing a year-over-year decline of 6.9% [4] - Total product revenue for Core Illumina was $880 million, compared to the average estimate of $869.69 million, showing a year-over-year decrease of 0.3% [4] - Service and other revenue was $161 million, below the average estimate of $170.12 million, with a significant year-over-year decline of 19.5% [4] - Sequencing instruments revenue reached $109 million, slightly above the estimated $108.51 million, reflecting a year-over-year decrease of 0.9% [4] - Core Illumina instruments revenue was $112 million, in line with the average estimate of $112.06 million, showing a year-over-year decline of 1.8% [4] - Sequencing consumables revenue was $696 million, exceeding the estimated $679.85 million, with a year-over-year decrease of 0.3% [4] - Microarrays instruments revenue was $3 million, below the estimated $3.61 million, representing a significant year-over-year decline of 25% [4] - Microarrays consumables revenue was $72 million, slightly below the average estimate of $74.59 million, with a year-over-year increase of 1.4% [4] - Overall, Core Illumina revenue was $1.04 billion, surpassing the average estimate of $1.03 billion, but reflecting a year-over-year decline of 1.4% [4] - Core Illumina consumables revenue was $768 million, exceeding the estimated $748.87 million, with a year-over-year decrease of 0.1% [4] Stock Performance - Illumina's shares returned 0.1% over the past month, compared to a 11.3% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Inseego reported a revenue of $31.67 million for the quarter ended March 2025, reflecting a decline of 29.6% year-over-year [1] - The earnings per share (EPS) was -$0.01, an improvement from -$0.36 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $32.07 million, resulting in a surprise of -1.23% [1] - The company achieved an EPS surprise of +85.71%, compared to the consensus estimate of -$0.07 [1] Revenue Breakdown - Mobile solutions revenue was $17.79 million, exceeding the two-analyst average estimate of $14.20 million [4] - Product revenues reached $19.69 million, slightly below the estimated $19.75 million [4] - Services and other revenues totaled $11.98 million, close to the estimated $12 million [4] - Fixed wireless access solutions revenue was $1.90 million, significantly lower than the average estimate of $5.55 million [4] Stock Performance - Inseego's shares have returned +8.1% over the past month, compared to the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Viewpoint - Hub Group reported a revenue of $915.22 million for the quarter ended March 2025, reflecting an 8.4% year-over-year decline and a surprise of -5.27% compared to the Zacks Consensus Estimate of $966.14 million [1] Group 1: Financial Performance - Earnings per share (EPS) for the quarter was $0.44, unchanged from the previous year, with an EPS surprise of +4.76% against the consensus estimate of $0.42 [1] - The company’s shares have returned -10.4% over the past month, contrasting with the Zacks S&P 500 composite's +11.3% change, indicating potential underperformance in the near term [3] Group 2: Revenue Breakdown - Operating Revenue from Intermodal and Transportation Solutions was $530.02 million, below the average estimate of $561.23 million, representing a year-over-year decline of 4% [4] - Operating Revenue from Inter-segment eliminations was -$25.81 million, better than the estimated -$28.63 million, but still reflecting a significant year-over-year change of -21.2% [4] - Operating Revenue from Logistics was $411 million, also below the average estimate of $446.60 million, marking a year-over-year decline of 14.4% [4]

Core Insights - McKesson reported revenue of $90.82 billion for the quarter ended March 2025, reflecting a 19% increase year-over-year, with EPS at $10.12 compared to $6.18 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $93.7 billion by 3.08%, while the EPS exceeded the consensus estimate of $9.81 by 3.16% [1] Revenue Breakdown - U.S. Pharmaceutical revenue was $83.17 billion, a 20.9% increase year-over-year, but below the average estimate of $85.79 billion [4] - Prescription Technology Solutions revenue reached $1.34 billion, up 13.5% year-over-year, slightly below the average estimate of $1.36 billion [4] - International revenue was $3.46 billion, showing a year-over-year decline of 2.5%, compared to the average estimate of $3.55 billion [4] - Medical-Surgical Solutions revenue was $2.85 billion, a 0.6% increase year-over-year, exceeding the average estimate of $2.79 billion [4] Adjusted Operating Profit - Adjusted Operating Profit for U.S. Pharmaceutical was $1.05 billion, matching the average estimate [4] - Adjusted Operating Profit for International was $102 million, surpassing the average estimate of $96.42 million [4] - Adjusted Operating Profit for Corporate was -$165 million, slightly worse than the average estimate of -$160.18 million [4] - Adjusted Operating Profit for Prescription Technology Solutions was $285 million, exceeding the average estimate of $267.80 million [4] - Adjusted Operating Profit for Medical-Surgical Solutions was $285 million, slightly above the average estimate of $283.33 million [4] Stock Performance - McKesson's shares returned +7.5% over the past month, underperforming compared to the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Arlo Technologies reported revenue of $119.07 million for Q1 2025, a year-over-year decline of 4.1% but exceeding the Zacks Consensus Estimate of $117.89 million by 1% [1] - The company achieved an EPS of $0.15, up from $0.09 a year ago, representing a surprise of 25% compared to the consensus estimate of $0.12 [1] Revenue Breakdown - Revenue from Services was $68.85 million, surpassing the average estimate of $67.79 million by analysts, and reflecting a year-over-year increase of 21.4% [4] - Revenue from Products was $50.22 million, slightly above the average estimate of $50.13 million, but showing a significant year-over-year decline of 25.6% [4] Margin Analysis - Non-GAAP gross margin for Services was reported at 83.1%, exceeding the two-analyst average estimate of 79% [4] - Non-GAAP gross margin for Products was -6.2%, which was below the two-analyst average estimate of -4.8% [4] Stock Performance - Over the past month, Arlo Technologies' shares have returned +10.3%, compared to the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]